Expression of mesothelin increases substantially during malignant transformation (Chang and Pastan, 1996; Jirsova et al., 2010), in particular, that associated with pancreatic cancer, mesothelioma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, endometrial cancer and cervical adenocarcinoma (Argani et al., 2001; Tchou et al., 2012; Iizuka et al., 2013; Qiao et al., 2014; Qiao et al., 2016; Stewart and Cristea, 2019; Weidemann et al., 2021). This evidence concerns the gene MSLN and pancreatic neoplasm.